New combo therapy aims to spare lymph nodes and boost rectal cancer outcomes
NCT ID NCT06507371
First seen Jun 25, 2026 · Last updated Jul 01, 2026 · Updated 3 times
Summary
This Phase III trial tests whether a modified short-course radiation that spares nearby lymph nodes, combined with chemotherapy (CAPOX) and the immunotherapy drug tislelizumab, works better than standard radiation plus chemotherapy for people with a certain type of rectal cancer (MSS). The study enrolls 170 patients with middle or low rectal cancer who want to avoid permanent colostomy. The main goal is to see if the new approach leads to a complete disappearance of the tumor after treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Tislelizumab (PD-1 antibody), capecitabine, oxaliplatin, and node-sparing short-course radiotherapy
What this could lead to
If successful, this could offer a more effective, less toxic treatment for rectal cancer that avoids damaging healthy lymph nodes and may help more patients avoid permanent colostomy.
What could go wrong
This is a Phase III trial, but the combination of immunotherapy and radiation is still experimental. Side effects from chemotherapy and immune-related reactions are possible, and the benefit over standard treatment is not yet proven.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECTAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Sir Run Run Shao hospital
Hanzhou, Zhejiang, 310016, China